RBC Capital Sticks to Its Hold Rating for Neumora Therapeutics, Inc. (NMRA)
In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on Neumora Therapeutics, Inc. (NMRA – Research ...
Goldman Sachs starts Sionna Therapeutics with Early-Stage Biotech designation
Goldman Sachs initiated coverage of Sionna Therapeutics (SION) with an Early-Stage Biotech designation. Lead assets SION-719 and SION-451 are ...
Investing Snacks5h
Vertex’s Journavx Poised for Big Outpatient Market Win
Vertex Pharmaceuticals secured a Buy rating from Leerink Partners analyst David Risinger. The firm’s newly approved pain ...
US close: Stocks sharply lower as Trump's tariffs reignite trade war
Wall Street stocks closed sharply lower on Tuesday as Donald Trump's tariffs on Canadian, Mexican and Chinese imports came ...
BioSpace4h
Rare Disease Biotechs Left in a Lurch as Congress Fails To Renew Priority Review Program
Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple effect is already being felt across biopharma.
Healthy Returns: AbbVie is the newest potential weight loss drug market player
AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra’s obesity drug. AI takes center stage at HIMSS ...
2minutemedicine.com20h
Vertex: non-opioid pain reliever Journavx shows success in post operative pain control
In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated ...